Portal de Periódicos da CAPES

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer

2017; American Association for Cancer Research; Volume: 24; Issue: 2 Linguagem: Inglês

10.1158/1078-0432.ccr-17-2136

1557-3265

Sana Intidhar Labidi‐Galy, Timothée Olivier, Manuel Rodrigues, Domenico Ferraioli, Olfa Derbel, Alexandre Bodmer, Patrick Petignat, Beata Rak, Nicolás Chopin, Olivier Trédan, Pierre‐Etienne Heudel, Sarah Stückelberger, Pierre Méeus, Patrick Meraldi, Valeria Viassolo, Aurélie Ayme, Pierre O. Chappuis, Marc‐Henri Stern, Claude Houdayer, Dominique Stoppa‐Lyonnet, Adrien Buisson, Lisa Golmard, Valérie Bonadona, Isabelle Ray‐Coquard,

CRISPR and Genetic Engineering

Purpose: BRCA2 plays a central role in homologous recombination by loading RAD51 on DNA breaks. The objective of this study is to determine whether the location of mutations in the RAD51-binding domain (RAD51-BD; exon 11) of BRCA2 gene affects the clinical outcome of ovarian cancer patients.Experimental Design: A study cohort of 353 women with ovarian cancer who underwent genetic germline testing for BRCA1 and BRCA2 genes was identified. Progression-free survival (PFS), platinum-free interval (PFI), and overall survival (OS) were analyzed. The Cancer Genome Atlas (TCGA) cohort of ovarian cancer (n = 316) was used as a validation cohort.Results: In the study cohort, 78 patients were carriers of germline mutations of BRCA2 After adjustment for FIGO stage and macroscopic residual disease, BRCA2 carriers with truncating mutations in the RAD51-BD have significantly prolonged 5-year PFS [58%; adjusted HR, 0.36; 95% confidence interval (CI), 0.20-0.64; P = 0.001] and prolonged PFI (29.7 vs. 15.5 months, P = 0.011), compared with noncarriers. BRCA2 carriers with mutations located in other domains of the gene do not have prolonged 5-year PFS (28%, adjusted HR, 0.67; 95% CI, 0.42-1.07; P = 0.094) or PFI (19 vs. 15.5 months, P = 0.146). In the TCGA cohort, only BRCA2 carriers harboring germline or somatic mutations in the RAD51-BD have prolonged 5-year PFS (46%; adjusted HR, 0.30; 95% CI, 0.13-0.68; P = 0.004) and 5-year OS (78%; adjusted HR, 0.09; 95% CI, 0.02-0.38; P = 0.001).Conclusions: Among ovarian cancer patients, BRCA2 carriers with mutations located in the RAD51-BD (exon 11) have prolonged PFS, PFI, and OS. Clin Cancer Res; 24(2); 326-33. ©2017 AACR.